Baird upgrades Amgen (Nasdaq: AMGN) from Neutral to Outperform, maintaining it $60 price target.

After approximately 2 years on ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE